A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells

Treatment of HER2+ breast cancer with trastuzumab is effective and combination anti-HER2 therapies have demonstrated benefit over monotherapy in the neoadjuvant and metastatic settings. This study investigated the therapeutic potential of targeting the BAG-1 protein co-chaperone in trastuzumab-respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadakis, Emmanouil, Robson, Natalia, Yeomans, Alison, Bailey, Sarah, Laversin, Stephanie, Beers, Stephen, Sayan, A. Emre, Ashton-Key, Margaret, Schwaiger, Stefan, Stuppner, Hermann, Troppmair, Jakob, Packham, Graham, Cutress, Ramsey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951334/
https://www.ncbi.nlm.nih.gov/pubmed/26958811
http://dx.doi.org/10.18632/oncotarget.7944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951334/
https://www.ncbi.nlm.nih.gov/pubmed/26958811
http://dx.doi.org/10.18632/oncotarget.7944

Ejemplares similares